Sponsor & Developer Portfolio

AstraZeneca

Clinical development pipeline, platform architecture, and registered trial tracking for AstraZeneca vaccine candidates.

3
Candidates
3
Target Diseases
4
Linked Studies

Development Phase Distribution

Phase 2 Clinical Trial: 2 Discontinued / Inactive: 1

Platform Technologies

Biological (unspecified platform): 3

Target Pathogens & Indications

COVID-19 Influenza RSV

Vaccine Pipeline Candidates (3)

Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.

Discontinued / Inactive ctgov-azd1222-astrazeneca

AZD1222

Target: COVID-19

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2023-04-19 (registry estimate)
Phase 2 Clinical Trial ctgov-azd4117-astrazeneca

AZD4117

Target: Influenza

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-01-28 (registry estimate)
Phase 2 Clinical Trial ctgov-azd6489-astrazeneca

AZD6489

Target: RSV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-10-01 (registry estimate)

Explore Other Vaccine Developers & Sponsors

Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.

View All Vaccine Developers →